The Multiple Myeloma Daily
A selection of articles, blog posts, videos and photos recommended by Robert Z. Orlowski
A selection of articles, blog posts, videos and photos recommended by Robert Z. Orlowski
Chimeric antigen receptor (CAR) T cells exhibit high response rates in B cell malignancies, but most patients eventually relapse. A key mechanism of treatment failure…
Teclistamab is an anti-CD3xBCMA bispecific antibody approved for use in relapsed/refractory multiple myeloma (MM). We undertook a retrospective study of post-approval, real-world outcomes with teclistamab…
Data from our prospectively maintained multicenter database revealed that 8.6% and 3.4% of symptomatic patients with WM developed a SPM and disease transformation, respectively, over…
This retrospective analysis examined 15 years of autologous stem cell transplantation (ASCT) for AL amyloidosis at Mayo Clinic (2010-2024). We aimed to assess ASCT utilization…
Multiple myeloma (MM) derives from the clonal proliferation of plasma cells, primarily residing in the bone marrow. However, MM cells can disseminate systemically, leading to…
BackgroundMultiple myeloma (MM) is virtually always preceded by monoclonal gammopathy of undetermined significance (MGUS). Elevated serum markers are used to classify MGUS patients into clinical…
Myeloma Paper of the Day, June 21st, suggested by Robert Orlowski / cancer, Emiko Sakaida, Kazumoto Shibuya, Marie Morooka, MM, Moeko Ogushi, Myeloma, Myeloma
Daratumumab- and elotuzumab-based regimens may be treatment options for refractory POEMS syndrome.